Latest Hotspot

JCR Pharmaceuticals Initiates Phase I Trial of JR-441 for Mucopolysaccharidosis Type IIIA

5 November 2024
3 min read

JCR Pharmaceuticals Co., Ltd. (TSE 4552; referred to as "JCR") has revealed that it has commenced dosing the first patient in Japan for the Phase I clinical trial of JR-441. This agent is an experimental enzyme replacement therapy aimed at treating mucopolysaccharidosis type IIIA (also known as Sanfilippo syndrome type A). JR-441 is a proprietary recombinant form of heparan N-sulfatase that has the ability to penetrate the blood-brain barrier (BBB).

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

MPS IIIA is a rare hereditary condition marked by pronounced symptoms affecting the central nervous system (CNS), and there are presently no approved therapies available. Preliminary research has indicated that JR-441 could potentially alleviate CNS-related symptoms linked to MPS IIIA.

This open-label, multicenter, single-arm trial is designed to evaluate the safety, biological effects, and pharmacokinetics of JR-441 in individuals between the ages of 1 and 18 years diagnosed with MPS IIIA. 

“MPS IIIA presents considerable challenges in managing CNS symptoms,” commented Dr. Kimitoshi Nakamura, Professor of Pediatrics at the Graduate School of Medical Sciences, Kumamoto University, and the study's medical expert. “This innovative treatment strategy signifies a new chapter in the management of this disorder. We have been looking forward to the chance to provide this therapy, and I am optimistic that its efficacy will be validated in clinical practice, ultimately enhancing the quality of life for both patients and their families.”

JR-441 has been granted Orphan Drug Designation by both the European Commission (EC) and the U.S. Food and Drug Administration (FDA), with a Phase I/II clinical trial currently ongoing in Germany that commenced in 2023 (JR-441-101, NCT06095388).

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

According to the data provided by the Synapse Database, As of November 5, 2024, there are 11 investigational drugs for the SGSH target, including 3 indication, 11 R&D institutions involved, with related clinical trial reaching 11, and as many as 1209 patents.

Posnafusp alfa is a drug classified as an antibody fusion protein, designed to target SGSH. The therapeutic areas of focus for this drug include congenital disorders, endocrinology and metabolic disease, skin and musculoskeletal diseases, as well as other diseases. The active indications for Posnafusp alfa are Mucopolysaccharidosis III and Glycogen Storage Disease IIIA.

图形用户界面, 文本, 应用程序

描述已自动生成

How to find the chemical modification of Inclisiran sodium?
Bio Sequence
6 min read
How to find the chemical modification of Inclisiran sodium?
5 November 2024
Inclisiran sodium is a novel small interfering RNA (siRNA) therapeutic developed by Alnylam Pharmaceuticals and commercialized by Novartis.
Read →
Numab Therapeutics Initiates Phase 1 Trial for NM32 in Solid Tumors
Latest Hotspot
3 min read
Numab Therapeutics Initiates Phase 1 Trial for NM32 in Solid Tumors
5 November 2024
Numab Therapeutics has begun a Phase 1 clinical trial for the NM32 program targeting patients with solid tumors.
Read →
Exploring Empagliflozin: Therapeutic Uses and Advances in Pharmaceutical Development
Chem Structure
3 min read
Exploring Empagliflozin: Therapeutic Uses and Advances in Pharmaceutical Development
5 November 2024
Empagliflozin is a medication used primarily to treat type 2 diabetes and, in some cases, to help manage heart failure.
Read →
Promising Phase 1a Results of PMN310 Shared by ProMIS Neurosciences at 17th Alzheimer’s Conference
Latest Hotspot
3 min read
Promising Phase 1a Results of PMN310 Shared by ProMIS Neurosciences at 17th Alzheimer’s Conference
5 November 2024
ProMIS Neurosciences Shares Encouraging Results from Phase 1a Trial of PMN310 at the 17th Alzheimer’s Disease Clinical Trials Conference.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.